Cytokinetics (NASDAQ: CYTK) CEO sells 7,500 shares, retains 407,830

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $59.62 per share. The transaction took place on April 29, 2026 and is classified as a non-derivative sale.

After this sale, Blum directly holds 407,830 shares of Cytokinetics common stock. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held indirectly by The Brittany Blum 2003 Irrevocable Trust.

Insider Trade Summary 10b5-1

Net Seller: 7,500 shares ($447,150)

Net Sell 3 txns

Insider Blum Robert I

Role President & CEO

Sold 7,500 shs ($447K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,500	$59.62	$447K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 407,830 shares (Direct, null); Common Stock — 2,083 shares (Indirect, by Trust 1)

Footnotes (1)

Shares held by The Bridget Blum 2003 Irrevocable Trust. Shares held by The Brittany Blum 2003 Irrevocable Trust.

Key Figures

Shares sold: 7,500 shares Sale price per share: $59.62 per share Direct holdings after sale: 407,830 shares +2 more

5 metrics

Shares sold 7,500 shares Open-market sale of Common Stock on April 29, 2026

Sale price per share $59.62 per share Price for the 7,500-share open-market sale

Direct holdings after sale 407,830 shares Common Stock directly owned by Robert I. Blum after transaction

Bridget Blum Trust holdings 2,083 shares Common Stock held by The Bridget Blum 2003 Irrevocable Trust

Brittany Blum Trust holdings 2,083 shares Common Stock held by The Brittany Blum 2003 Irrevocable Trust

Key Terms

open-market sale, non-derivative, indirect ownership, Irrevocable Trust, +1 more

5 terms

open-market sale financial

"Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"transaction_type: "non-derivative" for the 7,500-share sale"

indirect ownership financial

"ownership_type: "indirect" with nature_of_ownership by Trust 1 and Trust 2"

Irrevocable Trust financial

"Shares held by The Bridget Blum 2003 Irrevocable Trust."

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/29/2026 - 04:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/29/2026		S		7,500	D	$59.62	407,830	D
Common Stock								2,083	I	by Trust 1⁽¹⁾
Common Stock								2,083	I	by Trust 2⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CYTOKINETICS (CYTK) report for Robert I. Blum?

CYTOKINETICS reported that President & CEO Robert I. Blum completed an open-market sale of 7,500 shares of Common Stock. The transaction was a non-derivative sale executed on April 29, 2026, and is disclosed as a standard Form 4 insider trading report.

At what price did the CYTK CEO sell his 7,500 shares of Common Stock?

The 7,500 Cytokinetics shares were sold at $59.62 per share. This price reflects the transaction value used in the Form 4 disclosure for the open-market sale reported for President & CEO Robert I. Blum on April 29, 2026.

How many CYTOKINETICS (CYTK) shares does Robert I. Blum hold after the reported sale?

Following the reported sale, Robert I. Blum directly holds 407,830 shares of Cytokinetics Common Stock. The Form 4 also shows additional indirect holdings through two irrevocable trusts, each reporting ownership of 2,083 shares after the transaction date.

What indirect holdings in CYTOKINETICS (CYTK) are linked to Robert I. Blum?

Indirect holdings include 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust. These positions are reported as indirect ownership entries associated with Robert I. Blum in the Form 4 filing.

What type of transaction code is used for the CYTK CEO’s insider sale?

The insider sale is reported with transaction code “S,” which identifies a sale in an open market or private transaction. The filing classifies this as a non-derivative transaction in Cytokinetics Common Stock for President & CEO Robert I. Blum.

Does the CYTOKINETICS (CYTK) Form 4 show any option exercises or derivative trades?

The Form 4 does not report any derivative transactions or option exercises for this event. It lists a single non-derivative open-market sale of 7,500 shares and separate holding entries for indirect shares owned through two irrevocable trusts.